Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from manufacturing, marketing, selling, or distributing a generic version of such drug during any exclusivity period granted to manufacturers of generic brands.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S7928)
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line